Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
-$3.51B |
 |
AmgenAMGN |
-$168M |
 |
Editas MedicineEDIT |
-$7.4M |
 |
Crispr TherapeuticsCRSP |
-$164M |
 |
Catalyst PharmaceuticalsCPRX |
-$1.05B |
Are Ocugen Insiders Buying or Selling?
Ocugen (OCGN) has had 1 insider transaction in the past 90 days, all buys — insider buying is generally read as a bullish signal. The most recent was Johnson-Greene Treerita Essalima, who bought 21,000 shares at $1.23 on June 15, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the OCGN AI Score. For government officials trading this stock, see OCGN congressional trading.
Recent Ocugen Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Johnson-Greene Treerita Essalima | Jun 15, 2026 | Buy | 21,000 | $1.23 | $26,000 |
| Prabhavathi Fernandes | Nov 26, 2024 | Buy | 10,000 | $0.91 | $9,100 |
| Kirsten Castillo | Nov 22, 2024 | Buy | 25,000 | $0.91 | $23,000 |
Frequently Asked Questions: Ocugen Insider Trading
In the past 90 days, Ocugen insiders have made 1 buy and 0 sells. The net buying may indicate insider confidence in the company’s outlook.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Johnson-Greene Treerita Essalima has bought the most OCGN stock in the last 2 years, with a total value of $26,000.
According to our estimates, the total value of insider transactions for Ocugen in the last 2 years is positive, amounting to $58,000. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
